The Ivermectin Related Compound Moxidectin Can Target Apicomplexan Importin α and Limit Growth of Malarial Parasites
Cells · 2025
DOI: 10.3390/cells14010039 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Sujata B Walunj und 4 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Signaling Laboratory, Monash Biomedicine Discovery Institute, Department of Biochemistry and Molecular Biology, Monash University, Clayton, V…. Hauptthemen laut MEDLINE: Macrolides, Plasmodium falciparum, Ivermectin. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council Australia, Department of Science and Technology (DST), Science and Engineering Research Board, IITB/Monash University.
Abstract (Originalsprache)
Signal-dependent transport into and out of the nucleus mediated by members of the importin (IMP) superfamily is crucial for eukaryotic function, with inhibitors targeting IMPα being of key interest as anti-infectious agents, including against the apicomplexan Plasmodium species and Toxoplasma gondii, causative agents of malaria and toxoplasmosis, respectively. We recently showed that the FDA-approved macrocyclic lactone ivermectin, as well as several other different small molecule inhibitors, can specifically bind to and inhibit P. falciparum and T. gondii IMPα functions, as well as limit parasite growth. Here we focus on the FDA-approved antiparasitic moxidectin, a structural analogue of ivermectin, for its IMPα-targeting and anti-apicomplexan properties for the first time. We use circular dichroism and intrinsic tryptophan fluorescence measurements to show that moxidectin can bind directly to apicomplexan IMPαs, thereby inhibiting their key binding functions at low μM concentrations, as well as possessing anti-parasitic activity against P. falciparum in culture. The results imply a class effect in terms of IMPα’s ability to be targeted by macrocyclic lactone compounds. Importantly, in the face of rising global emergence of resistance to approved anti-parasitic agents, the findings highlight the potential of moxidectin and possibly other macrocyclic lactone compounds as antimalarial agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nuclear Signaling Laboratory, Monash Biomedicine Discovery Institute, Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Australia.
- Molecular Parasitology Laboratory, Department of Biosciences and Bioengineering, IIT Bombay, Powai, Mumbai 400076, India.
ORCID-Profile: Swati Patankar, David A Jans
Förderung
- National Health and Medical Research Council Australia
- Department of Science and Technology (DST), Science and Engineering Research Board
- IITB/Monash University
- Department of Biotechnology, India
Zitieren
APA
Walunj, S. B., Mishra, G., Wagstaff, K. M., Patankar, S., & Jans, D. A. (2025). The Ivermectin Related Compound Moxidectin Can Target Apicomplexan Importin α and Limit Growth of Malarial Parasites. Cells. https://doi.org/10.3390/cells14010039
Vancouver
Walunj SB, Mishra G, Wagstaff KM, Patankar S, Jans DA. The Ivermectin Related Compound Moxidectin Can Target Apicomplexan Importin α and Limit Growth of Malarial Parasites. Cells. 2025. doi:10.3390/cells14010039
BibTeX
@article{Walunj2025,
author = {Walunj, Sujata B and Mishra, Geetanjali and Wagstaff, Kylie M and Patankar, Swati and Jans, David A},
title = {The Ivermectin Related Compound Moxidectin Can Target Apicomplexan Importin α and Limit Growth of Malarial Parasites},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14010039}
}
EUVIMED